Chen J, Shen R, Zhu J, Wang Y, Fu L, Chen Y
Funct Integr Genomics. 2025; 25(1):56.
PMID: 40053129
DOI: 10.1007/s10142-025-01561-w.
Knezevic B, Radevic T, Petronijevic M
Medicina (Kaunas). 2025; 61(2).
PMID: 40005448
PMC: 11857375.
DOI: 10.3390/medicina61020334.
Auger S, Mishra V, Singh A, Miao Y, Agrawal N, Izumchenko E
Acad Oncol. 2025; 1(2).
PMID: 39867572
PMC: 11760339.
DOI: 10.20935/acadonco7456.
Huang X, Tang Y
PeerJ. 2025; 13():e18783.
PMID: 39822977
PMC: 11737332.
DOI: 10.7717/peerj.18783.
Liang H, Fang C, Qiu M
Sci Rep. 2025; 15(1):159.
PMID: 39747499
PMC: 11695685.
DOI: 10.1038/s41598-024-83921-3.
The cellular signaling crosstalk between memory B cells and tumor cells in nasopharyngeal carcinoma cannot be overlooked: Their involvement in tumor progression and treatment strategy is significant.
Li H, Bian Y, Xiahou Z, Zhao Z, Zhao F, Zhang Q
J Cancer. 2025; 16(1):288-314.
PMID: 39744570
PMC: 11660138.
DOI: 10.7150/jca.101420.
Prevalence of mental disorders and their associations with age at diagnosis and time since diagnosis of nasopharyngeal cancer.
Wang W, Wu Y, Qi L, Wu A, Zhu Y, Gong W
Front Public Health. 2024; 12:1469001.
PMID: 39697293
PMC: 11653364.
DOI: 10.3389/fpubh.2024.1469001.
GNA14 may be a potential prognostic biomarker in nasopharyngeal carcinoma.
Hao J, Yu X, Xiong L, Deng L, Lian S, Sun S
Front Oncol. 2024; 14:1482038.
PMID: 39659788
PMC: 11628407.
DOI: 10.3389/fonc.2024.1482038.
Concurrent chemoradiotherapy with S-1 platinum in the treatment of locoregionally advanced nasopharyngeal carcinoma: a multicenter, retrospective, propensity score-matched analysis.
Bian C, Zheng Z, Su J, Chang S, Yu H, Bao J
Front Pharmacol. 2024; 15:1394754.
PMID: 39568579
PMC: 11576306.
DOI: 10.3389/fphar.2024.1394754.
A prognostic nomogram for patients with III-IV nasopharyngeal carcinoma based on dynamic changes in the inflammatory and nutrition index.
Cheng G, Yuan S, Wang J, Deng S, Wu Y, Wang Y
Clin Transl Oncol. 2024; .
PMID: 39531145
DOI: 10.1007/s12094-024-03781-1.
Creating an interactive database for nasopharyngeal carcinoma management: applying machine learning to evaluate metastasis and survival.
Sun Y, Tan J, Li C, Yu D, Chen W
Front Oncol. 2024; 14:1456676.
PMID: 39435292
PMC: 11491431.
DOI: 10.3389/fonc.2024.1456676.
ADAR1-regulated miR-142-3p/RIG-I axis suppresses antitumor immunity in nasopharyngeal carcinoma.
Xu H, Li W, Xue K, Zhang H, Li H, Yu H
Noncoding RNA Res. 2024; 10:116-129.
PMID: 39351449
PMC: 11439846.
DOI: 10.1016/j.ncrna.2024.08.003.
Recent advances in early detection of nasopharyngeal carcinoma.
Jiang W, Zheng B, Wei H
Discov Oncol. 2024; 15(1):365.
PMID: 39177900
PMC: 11343961.
DOI: 10.1007/s12672-024-01242-3.
Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma.
Yu Y, Zhou P, Zhou R, Lin Q, Wu S
Ann Med. 2024; 56(1):2383959.
PMID: 39086168
PMC: 11295678.
DOI: 10.1080/07853890.2024.2383959.
Predictive function of tumor burden-incorporated machine-learning algorithms for overall survival and their value in guiding management decisions in patients with locally advanced nasopharyngeal carcinoma.
Liu Y, Sun S, Zhang Y, Huang X, Wang K, Qu Y
J Natl Cancer Cent. 2024; 3(4):295-305.
PMID: 39036668
PMC: 11256522.
DOI: 10.1016/j.jncc.2023.10.002.
PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials.
Xu R, Wong C, Chan K, Chiang C
Front Oncol. 2024; 14:1386381.
PMID: 38887234
PMC: 11180873.
DOI: 10.3389/fonc.2024.1386381.
New T staging recommendations for recurrent nasopharyngeal carcinoma.
Zhu M, Li P, Zhang H, Wu L, Min K
J Cancer Res Clin Oncol. 2024; 150(6):298.
PMID: 38850403
PMC: 11162391.
DOI: 10.1007/s00432-024-05821-3.
Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy.
Shen H, Zhang C, Li S, Liang Y, Lee L, Aggarwal N
Nat Commun. 2024; 15(1):4343.
PMID: 38773197
PMC: 11109227.
DOI: 10.1038/s41467-024-48661-y.
Polygenic risk-stratified screening for nasopharyngeal carcinoma in high-risk endemic areas of China: a cost-effectiveness study.
Yang D, Miller J, Xue W, Tang M, Lei L, Zheng Y
Front Public Health. 2024; 12:1375533.
PMID: 38756891
PMC: 11097958.
DOI: 10.3389/fpubh.2024.1375533.
A head-to-head comparison of [Ga]Ga-DOTATATE and [Ga]Ga-FAPI PET/CT in patients with nasopharyngeal carcinoma: a single-center, prospective study.
Zheng J, Wang G, Ru Q, Yang Y, Su L, Lv W
Eur J Nucl Med Mol Imaging. 2024; 51(11):3386-3399.
PMID: 38724654
DOI: 10.1007/s00259-024-06744-4.